Polymorphic form of reduced beta-nicotinamide mononucleotide disodium salt, and preparation method therefor and use thereof
AssigneeEffepharm (Shanghai) Co., Ltd.
InventorsXing Gao, Jianjun Yu, Qiang Shen, Qinyuan Xu, Yinshan Li, Jialing Liu, Liulei Chang
Life of this patent
Estimating the term…
Abstract
A polymorph of a reduced β-nicotinamide mononucleotide disodium salt, and a preparation method therefor and the use thereof as a pharmaceutical ingredient, a healthcare product ingredient, a cosmetic ingredient, or a food additives, and a preparation containing the salts are provided. A polymorph of NMNH disodium salt has excellent solubility, stability, flow performance, and hygroscopicity resistance. Its purification effects is better than that of amorphous forms.
Claims14
A crystal of a reduced β-nicotinamide mononucleotide disodium salt of formula (I), wherein the crystal is a hydrate of reduced β-nicotinamide mononucleotide disodium salt, and crystal form of the crystal is crystal form A, crystal form B or crystal form C,
- wherein the XRPD pattern of the crystal form A comprises 5 or more 20 values selected from the group consisting of:
- 12.7°±0.2°, 15.9°±0.2°, 18.0°=0.2°, 20.4°±0.2°, 20.9°=0.2°, and 31.8°±0.2°;
- the XRPD pattern of the crystal form B comprises 5 or more 20 values selected from the group consisting of:
- 12.0°±0.2°, 14.5°=0.2°, 15.3°±0.2°, 17.5°±0.2°, 19.9°±0.2°, and 21.5°±0.2°;
- and the XRPD pattern of the crystal form C comprises 5 or more 20 values selected from the group consisting of:
- 6.3°±0.2°, 15.3°±0.2°, 17.7°±0.2°, 19.9°±0.2°, 20.2°±0.2°, and 21.5°=0.2°.
Dependencies are inferred from the claim text.